Sarepta Therapeutics, Inc. (SRPT)

Market Cap	1.99B -81.4%
Revenue (ttm)	2.41B +47.1%
Net Income	-271.51M
EPS	-2.77
Shares Out	104.79M
PE Ratio	n/a
Forward PE	228.28
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,231,149
Open	18.86
Previous Close	18.84
Day's Range	18.73 - 19.25
52-Week Range	10.42 - 109.55
Beta	0.39
Analysts	Hold
Price Target	25.76 (+35.79%)
Earnings Date	Feb 25, 2026

About SRPT

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 3, 1997
• Employees: 1,372
• Stock Exchange: NASDAQ
• Ticker Symbol: SRPT
• Website: https://www.sarepta.com

Analyst Summary

According to 28 analysts, the average rating for SRPT stock is "Hold." The 12-month stock price target is $25.76, which is an increase of 35.79% from the latest price.

Price Target

$25.76

(35.79% upside)

Analyst Consensus: Hold